Dimera, Inc.

Portland, OR 97238

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $3.12MM
First Award Date 08/13/98
Most Recent Award Date 04/01/05

Key Personnel

Last Name Name Awards Contact
Hermsmeyer R Kent Hermsmeyer 8

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/05 - 03/31/09

DESCRIPTION (provided by applicant): This Phase II project continues with studies of rhesus monkeys in vivo to further test, and develop toward approval as a drug for human use, a novel estrogen receptor beta (ERbeta or ERb) selective (over ERalpha or ERa) agonist that is hypothesized to be effective for maintaining function of coronary arteries...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 03/31/05

DESCRIPTION (provided by applicant): This Phase II project continues with studies of rhesus monkeys in vivo to further test, and develop toward approval as a drug for human use, a novel estrogen receptor beta (ERbeta or ERb) selective (over ERalpha or ERa) agonist that is hypothesized to be effective for maintaining function of coronary arteries...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/07/03 - 04/30/04

DESCRIPTION (provided by applicant): The objective of this Phase I project is to test and develop, using primate coronary artery vascular muscle cells in vitro, a novel estrogen receptor beta (ERbeta) selective (over ERalpha) agonist that is highly effective for protecting coronary arteries against hyperreactivity and also for relieving cardiova...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/29/00 - 08/31/04

The objective of this project is to further develop a new progesterone formulation that is effective for hormone replacement therapy-protecting the coronary arteries against hyperreactivity. Such hyperreactivity results from the deficiency of progesterone after the cessation of ovarian function after menopause during the normal aging process. Th...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/00 - 08/31/04

The objective of this project is to further develop a new progesterone formulation that is effective for hormone replacement therapy-protecting the coronary arteries against hyperreactivity. Such hyperreactivity results from the deficiency of progesterone after the cessation of ovarian function after menopause during the normal aging process. Th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/00 - 08/31/01

The objective of this project is to develop new estriol formulation(s) that are effective as hormone replacement therapy-protecting the coronary arteries against hyperreactivity and relieving cardiovascular menopausal symptoms of ovarian steroid deficiency. Such coronary hyperreactivity results at least in part from the deficiency of estrogens a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/99 - 08/31/00

The objective of this project is to further develop a new progesterone formulation that is effective for hormone replacement therapy-protecting the coronary arteries against hyperreactivity. Such hyperreactivity results from the deficiency of progesterone after the cessation of ovarian function after menopause during the normal aging process. Th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/13/98 - 09/14/99

The objective of this project is to develop new progesterone formulation(s) that are effective as hormone replacement therapy-- protecting the coronary arteries against hyperreactivity. Such hyper- reactivity results from the deficiency of progesterone after the cessation of ovarian fu...